Literature DB >> 15497547

Management of magnetic intravitreal foreign bodies in 71 eyes.

Masoud Soheilian1, Abbas Abolhasani, Hamid Ahmadieh, Mohsen Azarmina, Mohammad H Dehgan, Arman Mashavekhi, Farshid Siadat, Andrew A Moshfeghi, Gholam A Peyman.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate the management of a series of eyes with magnetic intravitreal foreign bodies. PATIENTS AND METHODS: This retrospective review examined consecutive cases of ocular injury associated with intraocular foreign bodies; 71 eyes included had a single metallic intraocular foreign body (< 5 mm) located in the vitreous cavity removed by external magnet or intraocular forceps. Variables included preoperative and postoperative visual acuity, retinal break formation, retinal detachment, presence of an afferent pupillary defect, intraocular pressure, entrance site, foreign body size, method of extraction, and time between occurrence and surgical extraction.
RESULTS: Factors predictive of good visual outcome (visual acuity > 20/200) were: shortest interval between trauma and foreign body extraction, preoperative visual acuity of 20/200 or better, and absence of afferent pupillary defect.
CONCLUSIONS: In this nonrandomized study, good visual results could be obtained in eyes undergoing prompt foreign body removal, especially those with good preoperative visual acuity and no afferent pupillary defect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497547

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Predictive factors and outcomes of posterior segment intraocular foreign bodies.

Authors:  J Choovuthayakorn; L Hansapinyo; N Ittipunkul; D Patikulsila; P Kunavisarut
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

2.  Surgical outcomes of the removal of posterior segment metallic intraocular foreign bodies.

Authors:  Kai-Ling Peng; Ya-Hsin Kung; Pyn-Sing Hsu; Tsung-Tien Wu
Journal:  BMC Ophthalmol       Date:  2020-07-06       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.